+

WO2008110740A1 - Compositions topiques ayant des particules en suspension - Google Patents

Compositions topiques ayant des particules en suspension Download PDF

Info

Publication number
WO2008110740A1
WO2008110740A1 PCT/GB2008/000255 GB2008000255W WO2008110740A1 WO 2008110740 A1 WO2008110740 A1 WO 2008110740A1 GB 2008000255 W GB2008000255 W GB 2008000255W WO 2008110740 A1 WO2008110740 A1 WO 2008110740A1
Authority
WO
WIPO (PCT)
Prior art keywords
oil
compositions
constituent
cps
topical
Prior art date
Application number
PCT/GB2008/000255
Other languages
English (en)
Inventor
Sandra Judith Guerra-Vega
Rachel Koontz
William Mario Lenzetti
Haoming Yuan
Original Assignee
Reckitt Benckiser Inc
Reckitt Benckiser (Uk) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Inc, Reckitt Benckiser (Uk) Limited filed Critical Reckitt Benckiser Inc
Publication of WO2008110740A1 publication Critical patent/WO2008110740A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8152—Homopolymers or copolymers of esters, e.g. (meth)acrylic acid esters; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/54—Polymers characterized by specific structures/properties
    • A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
    • A61K2800/5422—Polymers characterized by specific structures/properties characterized by the charge nonionic

Definitions

  • the present invention relates to foaming topical compositions particularly adapted for application to human skin. More particularly, the compositions according to the invention are directed to topical compositions which provide good foaming and in addition to providing a cleaning benefit, are also intended to provide an antimicrobial benefit.
  • Topical compositions per se, are well-known in the cosmetic, dermatological as well as in the pharmaceutical fields. Most topical compositions are intended to provide at least one but generally provide two or more specific benefits after being applied to the human skin.
  • personal care compositions which are primarily intended to be soaps for general cleaning of the human skin such as hand soaps or body wash soaps are well known in the fields of cosmetics and personal care products. While providing a primary cleaning benefit, such personal care compositions frequently also provide ancillary benefits such as moisturizing and nourishing the skin.
  • compositions of the present invention are directed to providing at least two primary technical benefits, the first technical benefit being providing effective cleaning and the second technical benefit being efficacy in the reduction of undesired microorganisms, particularly in the reduction of both gram positive and/or gram negative microorganisms on a topical surface, e.g., skin, hair, scalp, etc.
  • the present inventive compositions may also provide one or more further ancillary technical benefits, e.g., skin conditioning and/or skin moisturizing.
  • further optional and ancillary benefits may be provided by the presence of one or more for the optional constituents which may be included in formulations or compositions according to the present intervention.
  • an improved foaming topical composition for the application to human body particularly to the skin or hair and most preferably to the skin which composition provides both providing effective cleaning and a reduction of undesired microorganisms, particularly in the reduction of both gram positive and/or gram negative microorganisms which may be present on the topical surface of the human body to which the topical compositions have been applied.
  • a foaming topical composition according to the first aspect of the invention wherein the topical composition provides a reduction of undesired microorganisms at least 30 minutes, preferably at least 45 minutes, more preferably at least 60 minutes after application to the human body.
  • an improved method for the treatment of the skin as well as other body surface including the hair which method contemplates the application of a cleaning and/or antimicrobially effective amount of the foaming topical composition described herein in order to provide an effective cleaning and/or antimicrobial b enefit.
  • compositions which provides a topical antimicrobial benefit, which compositions comprise: an anionic surfactant constituent, preferably necessarily comprising one or more anionic sulfate surfactants; optionally but preferably a co-surfactant constituent, especially preferably a betaine surfactant; .
  • a thickener system which necessarily comprises a polyacrylate cross-polymer thickener constituent with one or more polysaccharide polymers selected from xanthan gum, guar gum, locust bean gum, tragacanth gum, or derivatives thereof, especially a guar gum or guar gum derivative; an antimicrobial constituent which necessarily includes salicylic acid, salicylic acid salt or salicylate in conjunction with at least one further antimicrobially active compound or material which is effective against gram negative and/or gram positive bacteria; a cosmetic particulate constituent; optionally one or more optional constituents which may be used to impart one or more desired esthetic or technical benefits to the topical compositions and which is compatible with the other constituents present in the composition; wherein the said topical compositions are at an acidic pH, preferably at a pH of about 5 less and further wherein the compositions exhibit a viscosity of at least about least about 500 cps at 2O 0 C, preferably a viscosity of at least about 4
  • the aqueous foaming topical compositions of the invention exhibit antimicrobial efficacy both when contacted with a topical surface, e.g., human skin, other body surfaces or other similar substrate, as well as provides a reduction of undesired microorganisms at least 30 minutes, preferably at least 45 minutes, more preferably at least 60 minutes after application to a topical surface, body surface or other similar substrate.
  • a topical surface e.g., human skin, other body surfaces or other similar substrate
  • a method for the topical treatment of the human body or part thereof which method contemplates the step of applying the aqueous foaming topical compositions in order to provide a cleaning treatment and/or topical antimicrobial treatment to the human body or part thereof to which the said compositions are applied.
  • an aqueous foaming topical compositions which comprises a storage stable suspension of cosmetic particulate constituent.
  • compositions of the invention necessarily include one or more anionic surfactants and/or salt forms thereof.
  • anionic surfactants include alcohol sulfates and sulfonates, alcohol phosphates and phosphonates, alkyl ester sulfates, alkyl diphenyl ether sulfonates, alkyl sulfates, alkyl ether sulfates, sulfate esters of an alkylphenoxy polyoxyethylene ethanol, alkyl monoglyceride sulfates, alkyl sulfonates, alkyl ether sulfates, alpha-olefin sulfonates, beta-alkoxy alkane sulfonates, alkyl ether sulfonates, ethoxylated alkyl sulfonates, alkylaryl sulfonates, alkylaryl sulfates, alkyl monoglyceride sulfonates, alkyl carb
  • anionic surfactants include water soluble salts or acids of the formula (ROSO 3 ) X M or (RSO 3 ) X M wherein R is preferably a C 6 -C 24 hydrocarbyl, preferably an alkyl or hydroxyalkyl having a Ci 0 -C 2O alkyl component, more preferably a C 12 -C 18 alkyl or hydroxyalkyl, and M is H or a mono-, di- or tri-valent cation, e. g., an alkali metal cation (e. g., sodium, potassium, lithium), or ammonium or substituted ammonium (e.
  • R is preferably a C 6 -C 24 hydrocarbyl, preferably an alkyl or hydroxyalkyl having a Ci 0 -C 2O alkyl component, more preferably a C 12 -C 18 alkyl or hydroxyalkyl
  • M is H or a mono-, di- or tri-valent cation, e
  • methyl-, dimethyl-, and trimethyl ammonium cations and quaternary ammonium cations such as tetramethyl-ammonium and dimethyl piperdinium cations and quaternary ammonium cations derived from alkylamines such as ethylamine, diethylamine, triethylamine, and mixtures thereof, and the like) and x is an integer, preferably 1 to 3, most preferably 1.
  • alkylamines such as ethylamine, diethylamine, triethylamine, and mixtures thereof, and the like
  • x is an integer, preferably 1 to 3, most preferably 1.
  • Materials sold under the Hostapur and Biosoft trademarks are examples of such anionic surfactants.
  • anionic surfactants which may find use in the inventic compositiosn include alkyl-diphenyl-ethersulphonates and alkyl-carboxylates.
  • Other anionic surfactants can include salts (including, for example, sodium, potassium, ammonium, and substituted ammonium salts such as mono-, di-and triethanolamine salts) of soap, C 6 -C 20 linear alkylbenzenesulfonates, C 6 -C 22 primary or secondary alkanesulfonates, C 6 -C 24 olefinsulfonates, sulfonated polycarboxylic acids prepared by sulfo nation of the pyrolyzed product of alkaline earth metal citrates, C 6 -C 24 alkylpolyglycolethersulfates, alkyl ester sulfates such as C 14- I 6 methyl ester sulfates; acyl glycerol sulfonates,
  • Anionic compounds which function both as surfactants and which also act as a hydrotrope may be included as well as either as part of the anionic surfactant constituent or as a co-surfactant as described hereinafter.
  • Exemplary hydtropes include, inter alia, benzene sulfonates, naphthalene sulfonates, C 1 -C 11 alkyl benzene sulfonates, naphthalene sulfonates, C 5 -C 11 alkyl sulfonates, C 6 -Cn alkyl sulfates, alkyl diphenyloxide disulfonates, and phosphate ester hydrotropes.
  • the hydrotropic compounds of the invention are often provided in a salt fonn with a suitable counterion, such as one or more alkali, or alkali earth metals, such as sodium or potassium, especially sodium.
  • a suitable counterion such as one or more alkali, or alkali earth metals, such as sodium or potassium, especially sodium.
  • other water soluble cations such as ammonium, mono-, di- and tri- lower alkyl, i.e., Ci-4 alkanol ammonium groups can be used in the place of the alkali metal cations.
  • Exemplary alkyl benzene sulfonates include, for example, isopropylbenzene sulfonates, xylene sulfonates, toluene sulfonates, cuniene sulfonates, as well as mixtures thereof.
  • Exemplary C 5 -C 11 alkyl sulfonates include hexyl sulfonates, octyl sulfonates, and hexyl/octyl sulfonates, and mixtures thereof.
  • Particularly useful hydrotrope compounds include benzene sulfonates, o-toluene sulfonates, m-toluene sulfonates, and p-toluene sulfonates; 2,3-xylene sulfonates, 2,4-xylene sulfonates, and 4,6-xylene sulfonates; cumene sulfonates, wherein such exemplary hydrotropes are generally in a salt form thereof, including sodium and potassium salt forms.
  • the anionic surfactant constituent of the inventive compositions necessarily comprise one or more anionic sulfate surfactants which provides good foaming when used, and which is resistant to being rinse off from the skin or other topical surface to which it is applied.
  • especially preferred anionic surfactants which provide such functions are alkyl sulfates especially alkyl ether sulfates, particularly C 8 -C 18 alkyl ether sulfates which have been observed by the present inventor to be more resistant to being rinsed off a topical surface to which they have been applied than many other anionic surfactants which are commonly used in personal cleaning compositions known to the art, including alpha-olefin sulfonates, particularly C 12 -C 16 olefin sulfonates such as sodium lauryl sulfate.
  • Such foaming anionic surfactants particularly the preferred alkyl ether sulfates exhibit high foaming and good lathering to the inventive compositions.
  • the anionic surfactant constituent comprise one or more anionic surfactants based on alkyl sulfates, particularly alkyl ether sulfates and especially one or more of those as described in the following Examples.
  • a major proportion of the anionic surfactant constituent consists of one or more alkyl sulfates especially alkyl ether sulfates, preferably at least 60%wt, more preferably at least 70%wt, and yet more preferably at least 75%wt.
  • the anionic surfactant constituent comprises alkyl sulfates especially alkyl ether sulfates, hi certain particularly preferred embodiments the anionic surfactant constituent comprises at least 90%wt, more preferably the anionic surfactant constituent consists essentially of one or more alkyl sulfates especially one or more alkyl ether sulfates
  • the anionic surfactant constituent may be present in any effective amount, and is preferably present in amounts of from l%wt. to 30%wt. based on the total weight of the composition of which they form a part.
  • the anionic surfactant constituent comprises 3 - 25%wt., preferably from 10 - 20% wt. based on the total weight of the foaming topical composition of which they form a part.
  • Particularly preferred amounts of the anionic surfactant constituent are disclosed with reference to one or more of the examples.
  • compositions of the invention may include, and preferably do include one or more further surfactants selected from nonionic, amphotheric and zwitterionic surfactants as co -surfactants to the anionic surfactant constituent, hi certain preferred embodiments a co-surfactant constituent is necessarily present and is most preferably a betaine surfactant.
  • Exemplary useful nonionic surfactants are those which include a hydrophobicic base portion, such as a long chain alkyl group or an alkylated aiyl group, and a hydrophilic chain portion comprising a sufficient number of ethoxy and/or propoxy moieties to render the nonionic surfactant at least partially soluble or dispersible in water.
  • a hydrophobicic base portion such as a long chain alkyl group or an alkylated aiyl group
  • a hydrophilic chain portion comprising a sufficient number of ethoxy and/or propoxy moieties to render the nonionic surfactant at least partially soluble or dispersible in water.
  • nonionic surfactants include ethoxylated alkylphenols, ethoxylated and propoxylated fatty alcohols, polyethylene glycol ethers of methyl glucose, polyethylene glycol ethers of sorbitol, ethylene oxidepropylene oxide block copolymers, ethoxylated esters of fatty (C 6 -C 24 ) acids, condensation products of ethylene oxide with long chain amines or amides, and mixtures thereof.
  • nonionic surfactants include, but are not limited to: methyl gluceth-10, PEG- 20 methyl glucose distearate, PEG-20 methyl glucose sesquistearate, C 11 -C 1S pareth-20, ceteth-8, ceteth-12, dodoxynol-12, laureth-15, PEG-20 castor oil, polysorbate 20, steareth-20, polyoxyethylene-10 cetyl ether, polyoxyethylene-10 stearyl ether, polyoxyethylene-20 cetyl ether, polyoxyethylene-10 oleyl ether, polyoxyethylene-20 oleyl ether, an ethoxylated nonylphenol, ethoxylated octylphenol, ethoxylated dodecylphenol, or ethoxylated fatty (C 6 -C 22 ) alcohol, including 3 to 20 ethylene oxide moieties, polyoxyethyiene-20 isohexadecyl ether, polyoxyethylene-23 glycerol laurate
  • Exemplary useful amphoteric surfactants include derivatives of secondary and tertiary amines having aliphatic radicals that are straight chain or branched, and wherein one of the aliphatic substituents contains from about 8 to 18 carbon atoms and at least one of the aliphatic substituents contains an anionic water-solubilizing group, e.g., a carboxy, sulfonate, or a sulfate group.
  • Non-limiting examples of compounds falling within this description include: sodium 3 -(dodecylamino propionate, sodium 3- (dodecylamino)propane-l -sulfonate, sodium 2-(dodecylamino)ethyl sulfate, sodium 2- (dimethylamino)octadecanoate, disodium 3-(N carboxymethyldodecylamino)propane-l- sulfonate, disodium octadecyliminodiacetate, sodium l-carboxymethyl-2- undecylimidazole, and sodium N,N-bis(2-hydroxyethyl)-2-sulfato-3- dodecoxypropylamine.
  • amphoteric surfactants include sarcosinates and taurates, amide sulfo succinates, and betaines including phosphobetaines. Further amphoteric surfactants, although not specifically elucidated herein but known to the art may also be used.
  • a co-surfactant constituent desirably it comprises one or more betaines.
  • exemplary useful betaine surfactants which may be represented by the general formula:
  • R 1 is an alkyl group containing from 8 to 18 carbon atoms, or the amido radical which may be represented by the following general formula: wherein: R is an alkyl group having from 8 to 18 carbon atoms, a is an integer having a value of from 1 to 4 inclusive, and R 2 is a C 1 -C 4 alkylene group.
  • R is an alkyl group having from 8 to 18 carbon atoms
  • a is an integer having a value of from 1 to 4 inclusive
  • R 2 is a C 1 -C 4 alkylene group.
  • betaines are dodecyl dimethyl betaine, cetyl dimethyl betaine, dodecyl amidopropyldimethyl betaine, tetradecyldimethyl betaine, tetradecylamidopropyldimethyl betaine, dodecyldimethylammonium hexanoate and particularly cocoamidopropyl betaine.
  • a co-surfactant constituent is necessarily present, and in certain particularly preferred embodiments a betaine surfactant is necessarily present.
  • the co-surfactant constituent may be present in any effective amount, and are preferably present in amounts of from 0.01 %wt. to 10%wt. based on the total weight of the composition of which they form a part.
  • the co-surfactant constituent comprises 0.1 - 8%wt, preferably from
  • the sole surfactants present in the inventive compositions are one or more anionic surfactants, concurrently with one or more betaine surfactants to the exclusion of other species of surfactants.
  • An optional but preferred additional constituent which may be present is a foam booster which improves the foaming characteristics of the anionic surfactant(s) present.
  • Preferred foam boosters are based on one or more alkanolamides which provide composition thickening, foam enhancement, and foam stability and in preferred embodiments of the invention are necessarily present.
  • Exemplary alkanolamides which provide such a foam boosting function include but are not limited to: cocamide MEA, cocamide DEA, soyamide DEA, lauramide DEA, oleamide MIPA, stearamide MEA, myristamide MEA, lauramide MEA, capramide DEA, ricinoleamide DEA, myristamide DEA, stearamide DEA, oleylamide DEA, tallowamide DEA, lauramide MIPA, tallowamide MEA, isostearamide DEA, isostearamide MEA, and mixtures thereof.
  • the one ore more alkanolamides are present in amounts of up to about 10%wt, but are preferably included in amounts of from about 0.1 - 10%wt. based on the total weight of the topical composition of which they form a part.
  • compositions of the invention also necessarily include a thickener system which necessarily comprises a polyacrylate cross-polymer thickener with one or more polysaccharide polymers such as xanthan gum, guar gum, locust bean gum, tragacanth gum, or derivatives thereof, especially a guar gum.
  • a thickener system which necessarily comprises a polyacrylate cross-polymer thickener with one or more polysaccharide polymers such as xanthan gum, guar gum, locust bean gum, tragacanth gum, or derivatives thereof, especially a guar gum.
  • the polyacrylate cross-polymer thickener desirably exhibits a viscosity of between 10,000 and 18,000 measured using a Brookfield RVT viscometer operating at 20 ipm, for a gel formed form a 2%wt. dispersion of the said polyacrylate cross-polymer thickener in 25°C water.
  • a particularly preferred polyacrylate cross-polymer thickener is commercially available as CARBOPOL AQUA CC (ex. Noveon) which is described to be a cross-linked acrylate copolymer OfC 1-4 alkyl(meth)acryalte amine functional monomers and a hydrophobe.
  • the polyacrylate cross-polymer thickener is advantageously present in an amount of from about 0.1 %wt. to about 6%wt, based on the total weight of the topical composition of which it forms a part.
  • the polyacrylate cross-polymer thickener is solely CARBOPOL AQUA CC to the exclusion of further polyacrylate based thickeners.
  • the thickener constituent also necessarily comprises one or more polysaccharide polymers selected from xanthan gum, guar gum, locust bean gum, tragacanth gum, or derivatives thereof, especially a guar gum.
  • the guar gum is polysaccharide derived from the guar plant, e.g., hydroxypropyl guar, but preferably the guar gum is a cationic derivative of a guar gum, such as guar hydroxypropyltrimonium chloride commercially available as, e.g., JAGUAR C-162 (ex. Rhodia)
  • the combination of the preferred polyacrylate cross-polymer thickener and the preferred polysaccharide polymers provides a surprisingly effective thickening benefit and concurrently excellent suspension of the cosmetic particulate constituent even subsequent to adverse storage conditions, especially storage at elevated temperatures (e.g., at least 50°C, especially at least 60 0 C) for one, but preferably two weeks.
  • inventive compositions may optionally include further thickeners which are not found to deleteriously affect the favorable technical characteristics of the present invention, especially the storage stability characteristics. These may additional constituents of the thickener system of the invention. As further optional thickener constituents, the inventive compositions may additionally include one or more polysaccharide based thickener constituents, e.g., naturally occurring or modified celluloses, further polycarboxylate polymers, further polyacrylamides, clays, and mixtures thereof.
  • polysaccharide based thickener constituents e.g., naturally occurring or modified celluloses, further polycarboxylate polymers, further polyacrylamides, clays, and mixtures thereof.
  • Exemplary cellulose based thickeners are those which are either naturally occurring or which may be based on modified or processed naturally occurring cellulose materials, e.g., cellulose, alkyl cellulose or cellulose derivatives including methyl cellulose ethyl cellulose, hydroxymethyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, ethylhydroxymethyl cellulose and ethyl hydroxy ethyl cellulose.
  • modified or processed naturally occurring cellulose materials e.g., cellulose, alkyl cellulose or cellulose derivatives including methyl cellulose ethyl cellulose, hydroxymethyl cellulose, hydroxy ethyl cellulose, hydroxy propyl cellulose, carboxy methyl cellulose, carboxy methyl hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose
  • the thickener system of the present invention is desirably present in a sufficient amount to provide a viscosity of at least 500 cps measured at room temperature to the inventive compositions.
  • the thickener system is present in a sufficient amount such that the final viscosity of the composition is at least: 500 cps, 750 cps, 900 cps, 1000 cps, 1200 cps, 1400 cps, 1500 cps, 1700 cps, 1900 cps, 2000 cps, 2200 cps, 2400 cps, 2600 cps, 2800 cps, 3000 cps, 3200 cps, 3400 cps, 3500 cps, 3600 cps, 3800 cps and especially preferably at least about 4000 cps when measured at room temperature (approx.
  • the thickener system of the present invention is desirably present in a sufficient amount to provide a viscosity of not more than 15000 cps measured at room temperature to the inventive compositions.
  • the thickener system is present in a sufficient amount such that the final viscosity of the composition is not more than: 15000 cps, 14000 cps, 13500 cps, 13000 cps, 12500 cps, 12000 cps, 11500 cps, 11000 cps, 10500 cps, 10000 cps, 9500 cps, 9000 cps, 8000 cps, 8500 cps and especially preferably not more than about 7500 cps when measured at room temperature using a Brookfield Type PV-III viscometer, with a #63 spindle operating at 6 ipm.
  • the thickener system of the present invention may be present in different amounts in order to achieve a desired viscosity within the foregoing preferred ranges, and may be present in any effective amount, advantageously the thickener system is present in amounts of from 0.05%wt. to 15%wt. based on the total weight of the topical composition of which it forms a part.
  • the thickener system comprises in order of increasing preference: 0.1 %wt, 0.5%wt., l%wt., 1.5%wt., 2%wt, 2.5%wt, and especially preferably at least 3%wt. based on the total weight of the topical composition of which they form a part.
  • the thickener system of the present invention comprises, in order of increasing preference, not more than 15%wt, 14%wt, 13%wt, 12.5%wt., 12%wt. ll%wt, 10.5%wt., 10%wt., 9.5%wt, 9%wt., and especially preferably not more than 8%wt. based on the total weight of the topical composition of which they it forms a part.
  • the compositions exclude all other thickeners other than the polyacrylate cross-polymer thickener with one or more polysaccharide polymers selected xanthan gum, guar gum, locust bean gum, tragacanth gum, or derivatives thereof, especially a guar gum or guar gum derivative.
  • compositions of the invention also necessarily include a cosmetic particulate constituent which is desirably dispersed and suspended in the composition.
  • the cosmetic particulate may be any particulate material which is a solid at room temperature (approx. 20°C) temperature and atmospheric pressure, which does not deleteriously react chemically with balance of the constituents of the inventive composition.
  • the cosmetic particulate is insoluble in balance of the constituents of the inventive composition, particularly when the compositions are brought to a temperature above room temperature and especially to a temperature of at least 5O 0 C and preferably at least 60 0 C for at least 24 hours, preferably for at least 48 hours.
  • the cosmetic particulate constituent exhibits a melting temperatures of at least 70 0 C, preferably at least 100 0 C, more preferably at least 120 0 C, and most preferably at least 130°C.
  • the cosmetic particulate composition may be absorbent or non-absorbent with respect to one or more of the remaining constituents of the inventive compositions of which they form a part.
  • the cosmetic particulate constituent may be mineral or organic, lamellar, spherical, viz., beads, or oblong. They may have a generally regular geometry, such as in the case of spheres or rods, or they may have an irregular geometry such as crushed particulate materials.
  • Exemplary materials useful for the cosmetic particulate constituent include: inorganic particulate particles formed from talc, mica, silica, kaolin, boron nitride, carbonates such as precipitated calcium carbonate, magnesium carbonate and magnesium hydrocarbonate, hydroxyapatite, hollow silica microspheres, glass microcapsules, and ceramic microcapsules, inorganic pigments and mixtures thereof.
  • Exemplary materials useful for the cosmetic particulate constituent include: organic particulate particles formed from polyamide powders, such as polyamides (Nylons), polyethylenes, polypropylenes, polyesters, acrylic polymers such as polymethyl methacrylate, polytetrafluoro ethylene (Teflons.), as well as crystalline and microcrystalline waxes derived from plants, mineral oils or petroleum, hollow polymer microspheres such as those formed from polyvinylidene chloride/acrylonitrile, starches, alginates, organic dyestuffs or pigments, and mixtures thereof. Mixtures of two or more cosmetic particles may be used to provide the cosmetic particulate constituent.
  • Preferred as the cosmetic particulate constituent are materials which provide an exfoliating benefit.
  • these cosmetic particulates have an apparent diameter in the range of from about 100 to about 1000 ⁇ m, preferably from about 100 to about 600 ⁇ m and most preferably from about from about 250 to about 600 ⁇ m.
  • An apparent diameter corresponds to the diameter of the circle in which the elementary particle is inscribed along its smallest dimension (thickness for lamellae).
  • a preferred class of cosmetic particulate materials are based on synthetically occurring or synthetic waxes inclusive of microcrystalline waxes. Exemplary useful waxes include any of those which are generally useful used in cosmetics and dermatology.
  • Exemplary waxes of natural origin include for instance beeswax, carnauba wax, candelilla wax, ouricoury wax, Japan wax, cork fibre wax or sugar cane wax, paraffin wax, lignite wax, microcrystalline waxes, lanolin wax, niontan wax, ozokerites, hydrogenated oils, for instance hydrogenated jojoba oil.
  • Exemplary waxes of synthetic origin include for instance polyethylene waxes derived from the polymerization of ethylene, waxes obtained by Fischer-Tropsch synthesis, esters of fatty acids and of glycerides that are solid at 50 0 C.
  • silicone waxes for instance alkyl, alkoxy, and/or esters of poly(di)methylsiloxane that are solid at 50°C. preferably at 60 0 C or higher temperatures.
  • These waxes may be formed particulates, e.g., beads or spheres according to conventional methods.
  • the cosmetic particulate constituent of the invention may be provided in any effective amount, but desirably is present in amount which are aethetically pleasing to the user of the composition.
  • the cosmetic particulate constituent is made of individual cosmetic particulate materials which may be of a uniform chemical or physical composition, and/or of a uniform size or dimension and/or of a uniform color but this is not a necessity and mixtures or different individual cosmetic particulate materials which may be differentiated on the basis of chemical and/or physical composition, and/or size or dimension and/or color may be provided as the cosmetic particulate constituent of the invention.
  • the cosmetic particulate constituent of the invention may be provided in any effective amount, advantageously the cosmetic particulate constituent form at least 0.01%wt., preferably at least 0.05%wt, and most preferably at least 0.1%wt of the topical composition. Similarly advantageously the cosmetic particulate constituent form not more than 10%wt, preferably not more than 5%wt, and yet more preferably not more than 2%wt, and most preferably not more than 2%wt of the topical composition of which it forms a part.
  • the dispersed cosmetic particulates present in the bulk phase of the topical compositions exhibit surprisingly good stability during storage, even subsequent to adverse storage conditions, especially storage at elevated temperatures (e.g., at least 50°C, especially at least 60 0 C) for one, but preferably two weeks.
  • the foaming topical compositions exhibit excellent suspension of the dispersed cosmetic particulates such that when the freshly made inventive compositions are vigorously manually shaken and then allowed to return to a quiescent state, such as by permitting them to stand on a tabletop or other surface at room temperature (approx. 20°C) for 48 hours, the majority of the dispersed cosmetic particulates do not drop or rise more than 5%, preferably do not drop or rise more than 3%, most preferably do not drop or rise more than 2% of their original distance from the bottom of the container in which the inventive composition is present when they have returned to a quiescent state following vigorous manual shaking.
  • major of the dispersed cosmetic particulates is meant to convey that at least 90% of, preferably at least 95% and most preferably at least 97% of the of the dispersed cosmetic particulates physically present in the compositions. This is a particularly attractive and characteristic feature of preferred embodiments of inventive compositions, as the suspended dispersed cosmetic particulates do not appear to move perceptibly over long periods of time.
  • At least 90% of, preferably at least 95% and most preferably at least 97% of the dispersed cosmetic particulates physically present in the bulk phase of the compositions do not drop or rise more than 5%, most preferably do not drop more than 2% of their original distance from the bottom of the container in which the inventive composition is present when they have returned to a quiescent state following manual shaking when measured after 72 hours, more preferably when measured after 168 hours, still more preferably when measured after 10 days, yet more preferably after 14 days when left in a quiescent state at room temperature.
  • At least 90% of, preferably at least 95% and most preferably at least 97% of the dispersed cosmetic particulates dispersed in the topical compositions do not drop or rise more than 5%, preferably 2% after 3 weeks and especially after 4 weeks when retained in a quiescent state at room temperature.
  • at least 90% of, preferably at least 95% and most preferably at least 97% of the dispersed cosmetic particulates dispersed in the topical compositions do not drop or rise more than 5%, preferably 2% after 1 week, preferably at least 2 weeks when retained in a quiescent state at 40°C, preferably at 50°C, yet more preferably at 55°C and most preferably at least 60°C.
  • inventive compositions also necessarily include an antimicrobial constituent which necessarily includes salicylic acid or salt form thereof, in conjunction with at least one further antimicrobially active compound or material which is effective against gram negative and/or gram positive bacteria, and which is compatible with the other constituents present in the composition.
  • the salicylic acid or salt form thereof is provided to the compositions of the invention in an antimicrobially effective amount.
  • salicylates including octyl, amyl, phenyl, benzyl, menthyl, glyceryl, and dipropyleneglycol esters thereof
  • inventive compositions are believed to be effective against gram positive and/or gram negative microorganisms as well.
  • the salicylic acid, salicylic acid salt and/or salicylate are present in amounts of from about from 0.001 - 3%wt, preferably in amounts from 0.01 - 2%wt, but are most desirably present in reduced weight percentages from about 0.05 - 0.5%wt. based on the total weight of the inventive composition of which they form a part.
  • the inventive compositions necessarily also include one further antimicrobially active compound or material which is effective against gram negative and/or gram positive bacteria, and which is compatible with the other constituents present in the composition.
  • exemplary useful compounds and materials which may be used as the further antimicrobially active compound or material include one or more of one or more antimicrobial agents including: pyrithiones (especially zinc pyrithione which is also known as ZPT), diniethyldimethylol hydantoin (Glydant®), methylchloroisothiazolinone/methylisothiazolinone (Kathon CG®), sodium sulfite, sodium bisulfite, imidazolidinyl urea (Germall 115®), diazolidinyl urea (Germaill II®), benzyl alcohol, 2-bromo-2-nitropropane-l,3-diol (Bronopol®), formalin (formalde
  • the one or more one further antimicrobially active compounds or materials are present in amounts of from about from 0.001 - 3%wt, preferably in amounts from 0.1 - 2%wt, but are most desirably present from about 0.1 - 0.5%wt. based on the total weight of the inventive composition of which they form a part.
  • the superior antimicrobial efficacy is provided when the inventive foaming topical compositions are also maintained in a specific acidic pH range, preferably of about 6 or less, preferably when the pH is maintained in the range of from about 2 - 5.5, more preferably when the pH is, in order of increasing preference, at least 2.2, 2.4, 2.5, 2.6, 2.8, 3, 3.2, 3.4, 3.5, 3.6, 3.8, 4, 4.1, and 4.2, while concurrently the pH is, in order of increasing preference is not more than 5.5, 5.4, 5.2, 5, 4.8, 4.7, 4.6, 4.5, 4.4 and 4.3.
  • a specific acidic pH range preferably of about 6 or less, preferably when the pH is maintained in the range of from about 2 - 5.5, more preferably when the pH is, in order of increasing preference, at least 2.2, 2.4, 2.5, 2.6, 2.8, 3, 3.2, 3.4, 3.5, 3.6, 3.8, 4, 4.1, and 4.2, while concurrently the pH is, in
  • the selection of the salicylic acid, salicyclic acid salt and/or salicylate(s) in conjunction with the one or more further antimicrobially active compounds or materials provide both rapid acting kill of undesired microorganisms when topically applied to the human skin, as well as possibly also providing a more durable antimicrobial benefit.
  • Such an antimicrobial benefit is highly advantageous in controlling bodily odors, as well as providing a general perception of freshness consequent upon the use of the inventive composition.
  • the topical compositions of the invention may include one or more further optional constituents which may be used to impart one or more desired esthetic or technical benefits to the topical compositions.
  • one or more of the following recited optional constituents maybe considered as essential constituents according to a particular preferred embodiment.
  • Such optional constituents include additives and adjuvants which are conventional in the cosmetic, pharmaceutical or dermatological field, such as hydrophilic or lipophilic gelling agents, hydrophilic or lipophilic active agents, humectants, opacifiers, preservatives, antioxidants, solvents especially organic solvents, pH adjusting agents, pH buffers, chealating agents, fragrances, fragrances or other materials which provide an aromatherapy benefit, fillers, preservatives, dyestuffs or colorants, and light stabilizers including UV absorbers.
  • the amounts of these various additives and adjuvants are those conventionally used in the field, and, for example, range from 0.01% to 10% of the total weight of the composition.
  • One optional constituent which may be included in the inventive compositions is a latex.
  • Such are used to provide opacification of the composition.
  • materials which are typically emulsions, dispersions or suspensions of a a water insoluble polymer or copolymer in an carrier.
  • the carrier may be aqueous, an aqeueous/organic solvent mixture or organic solvent.
  • the latex may be based on a homopolymer, or on copolymer. It is contemplated that the copolymer comprises two or more different monomers which are joined in either a block or random arrangement of the two or more different monomers.
  • Exemplary copolymers suitable for the latex emulsion include those formed from styrene, alpha-methylstyrene, divinylbenzene, acrylic acid, methacrylic acid, C 1 -C 20 esters of acrylic acid or methacrylic acid, acrylamide, methacrylamide, maleic acid, vinyl acetate, crotonic acid, vinyl neodecanoate and butenoic acid.
  • Examples of carboxylate type copolymers are the styrene/alkyl acrylate and partially esterified polyacrylic and polymethacrylic salts and free acid forms.
  • These copolymers may be prepared by polymerization of the respective monomers by traditional oil-in-water or water-in-oil emulsion polymerization techniques.
  • a pseudo latex may be prepared by esterification of preformed polymer with C 1 -C 20 alkanol.
  • Average diameters of the dispersed polymer may range from about 0.001 micron to about 120 micron, preferably from about 0.01 micron to about 1 micron, optimally from about 0.1 micron to about 0.5 micron.
  • Number average molecular weight for polymers according to the present invention may range from about 1,000 to about 1,000,000, preferably from about 2,000 to about 500,000, optimally from about 5,000 to about 20,000.
  • a variety of techniques well-known in the art can be used to prepare latexes of water-insoluble polymer particles. These include, inter alia, batch, semi-continuous and seeded emulsion polymerization techniques.
  • Latexes useful in the present invention are latexes presently commercially available under the trademark ACUSOL (ex. Rohm & Haas Inc.).
  • the latexes are characterized by pH of about 2 to about 3, having approximately 40% solids in water, with particle size of about 0.1 to about 0.5 micron. Specific ACUSOL.
  • polymers include ACUSOL OP301 described as being a latex of a styrene/acrylate polymer, ACUSOL OP302 described as being a latex of a styrene/acrylate/divinylbenzene copolymer, ACUSOL OP303 described as being a latex of a styrene/acrylamide copolymer, ACUSOL OP305 described as being a latex of a styrene/PEG-10 maleate/nonoxynol-10 maleate/acrylate copolymer and a styrene/acrylate/PEG-10 dimaleate copolymer.
  • Latexes useful in the present invention include those styrene/polyvinylpyrrolidone co-polymers and styrene/acrylic emulsions.
  • styrene/polyvinylpyrrolidone co-polymers which can be used include, for example, POLECTRON 430 (ex.
  • sodium styrene/acrylate/divinyl-benzene co-polymer and ammonium nonoxynol-4 sulfate sodium stytene/PEG-10 maleate/nonoxynol-10 maleate/acrylates co-polymer and ammonium nonoxynol-4 sulfate
  • the latex When present in a composition, in accordance with certain of the preferred embodiments, the latex may be present in amounts of up to about 5%wt., preferably are present in amounts of from about 0.001%wt. to about 3%wt, preferably are present in amount from about 0.1 %wt. to about 1.2%wt, and most preferably are present in amounts of from about 0.1 %wt. to about l%wt, based on the total weight of the topical composition of which it forms a part. Concurrently the amount of the of the water- insoluble polymer present in the latex may range from about 0.01 to about 90%, preferably from about 0.1 to about 60%, optimally from about 10 to about 50% by weight of the latex.
  • the topical compositions may also a cationic Polyquaternium-type polymer.
  • Such materials are, per se, well known to the art of topical compositions.
  • Various grades of such cationic polymers may be used, inter alia: Polyquaternium 1; Polyquaternium 2; copolymers of hydroxyethylcellulose and diallyldimethyl ammonium chloride commercially available as Polyquaternium 4; homopolymers of diallyldimethylammonium chloride commercially available as Polyquaternium 5; dimethyldiallyammonium chloride homopolymer commercially available as Polyquaternium 6; copolymers of diallyldimethylammonium chloride with acrylamide commercially available as Polyquaternium 7; the polymeric quaternary ammonium salt of methyl and steardyl dimethylaminoethyl methacrylate quatemized with dimethyl sulfate commercially available as Polyquaternium 8; the polymeric quaternary ammonium salt of poly
  • the one or more cationic Polyquaternium-type polymers are advantageously present in amounts of from about from 0.001 - 2.5 %wt., preferably in amounts from 0.01 - 2%wt, but are most desirably present in reduced weight percentages from about 0.05 - l%wt. based on the total weight of the topical composition of which they form a part.
  • the topical compositions may include one or more preservatives.
  • exemplary useful preservatives include compositions which comprise parabens, including methyl parabens and ethyl parabens, glutaraldehyde, formaldehyde, 2-bromo-2-nitropropoane- 1,3-diol, 5-chloro-2-methyl-4-isothiazolin-3-one, 2-methyl-4-isothiazoline-3-one, and mixtures thereof.
  • One exemplary composition is a combination 5-chloro-2-methyl-4- isothiazolin-3-one and 2-methyl-4-isothiazolin-3-one where the amount of either component may be present in the mixture anywhere from 0.001 to 99.99 weight percent, based on the total amount of the preservative.
  • the most preferred preservative are those commercially available preservative comprising a mixture of 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-3 ⁇ one marketed under the trademark KATHON CG/ICP as a preservative composition (ex. Rohm and Haas Inc.).
  • Further useful preservative compositions include KATHON CG/ICP II (ex. Rohm and Haas Inc.), PROXEL (ex. Zeneca), SUTTOCIDE A (ex.
  • the preservative is included in any amount found to be effective in retarding or inhibiting the grown of undesired microorganisms in the topical compositions, particularly during storage for several months at room temperature.
  • the preservative composition is advantageously present in amounts of up to about 1.5%wt, preferably are present in amounts of from about 0.00001%wt. to about 0.5%wt, and most preferably is present in an amount of from about 0.000 l%wt. to 0.1 %wt. based on the total weight of the topical composition of which it forms a part.
  • the topical compositions may include one or more fillers in the form of powders.
  • these powders include chalk, talc, kaolin, starch, smectite clays, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, aluminum starch octenyl succinate and mixtures thereof.
  • the one or more fillers may be present in amounts of up to about 5%wt., preferably are present in amounts of from about 0.001%wt. to about 5%wt. based on the total weight of the topical composition of which it forms a part.
  • the topical compositions may include a fragrance constituent, which may be based on natural and synthetic fragrances and most commonly are mixtures or blends of a plurality of such fragrances, optionally in conjunction with a carrier such as an organic solvent or a mixture of organic solvents in which the fragrances are dissolved, suspended or dispersed.
  • a fragrance constituent which may be based on natural and synthetic fragrances and most commonly are mixtures or blends of a plurality of such fragrances, optionally in conjunction with a carrier such as an organic solvent or a mixture of organic solvents in which the fragrances are dissolved, suspended or dispersed.
  • natural fragrances include the extracts of blossoms (lily, lavender, rose, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, caraway, juniper), fruit peel (bergamot, lemon, orange), roots (nutmeg, angelica, celery, cardamon, costus, iris, calmus), woods (pinewood, sandalwood, guaiac wood, cedarwood, rosewood), herbs and grasses
  • tarragon lemon grass, sage, thyme
  • needles and branches spruce, fir, pine, dwarf pine
  • resins and balsams galbanum, elemi, benzoin, myrrh, olibanum, opoponax
  • Menthol may be advantageously ncluded in that it also provides a cooling sensation when topically applied.
  • Animal raw materials for example civet and beaver, may also be used.
  • Typical synthetic perfume compounds are products of the ester, ether, aldehyde, ketone, alcohol and hydrocarbon type.
  • perfume compounds of the ester type are benzyl acetate, phenoxyethyl isobutyrate, p-tert.butyl cyclohexylacetate, linalyl acetate, dimethyl benzyl carbinyl acetate, phenyl ethyl acetate, linalyl benzoate, benzyl formate, ethylmethyl phenyl glycinate, allyl cyclohexyl propionate, styrallyl propionate and benzyl salicylate.
  • Ethers include, for example, benzyl ethyl ether while aldehydes include, for example, the linear alkanals containing 8 to 18 carbon atoms, citral, citronellal, citronellyloxyacetaldehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal.
  • suitable ketones are the ionones, alpha-isomethylionone and methyl cedryl ketone.
  • Suitable alcohols are anethol, citronellol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol.
  • the hydrocarbons mainly include the terpenes and balsams.
  • perfume oils are essential oils of relatively low volatility which are mostly used as aroma components. Examples are sage oil, camomile oil, clove oil, melissa oil, mint oil, cinnamon leaf oil, lime-blossom oil, juniper berry oil, vetiver oil, olibanum oil, galbanum oil, labolanum oil and lavendin oil.
  • a further useful material which finds use in the fragrance constituent is famesol which is the common chemical name for 3,7,1 l-trimethyldodeca-2,6,10-trienol, which is commercially available from a number of sources and has found use in cosmetic compositions, primarily as a fragrance constituent.
  • the fragrance constituent may be present in any effective amount such that it can be discerned by a consumer of the topical composition, however is advantageously present in amounts of up to about 0.5%wt, preferably are present in amounts of from about 0.0000 l%wt. to about 0.3 %wt, and most preferably is present in an amount of from about 0.0001%wt. to 0.25%wt. based on the total weight of the composition of which it forms apart.
  • the inventive compositions may include one or more colorants, e.g, dyes or pigments which are known to the art be useful in cosmetic or topical compositions which may be used to impart a desired color or tint to the inventive compositions.
  • Any colorant which is compatible with the other constituents forming the topical compositions may be used and such may be present in any amount effective to achieved the desired visual effect.
  • Exemplary colorants include pigments, inter alia, inorganic red pigments, such as iron oxide, iron hydroxide and iron titanate; inorganic brown pigments, such as .gamma.
  • one or more colorants maybe added in amounts of about 0.001 %wt. to about 0.1 % by weight, based on the total weight of the composition of which the colorant(s) forms apart.
  • the topical compositions may comprise one or more humectants, including polyhydric alcohols including polyalkylene glycols as well as alkylene polyols and their derivatives, inter alia, including propylene glycol, dipropylene glycol, polypropylene glycol, polyethylene glycol and derivatives thereof, sorbitol, hydroxypropyl sorbitol, erythritol, threitol, pentaerythritol, xylitol, glucitol, mannitol, hexylene glycol, butylene glycol (e.g., 1,3-butylene glycol), hexane triol (e.g., 1,2,6-hexanetriol), glycerine, ethoxylated glycerine and propoxylated glycerine.
  • polyhydric alcohols including polyalkylene glycols as well as alkylene polyols and their derivatives, inter alia,
  • humectants include sodium 2-pyrrolidone-5-carboxylate, guanidine; glycolic acid and glycolate salts (e.g. ammonium and quaternary alkyl ammonium); lactic acid and lactate salts (e.g. ammonium and quaternary alkyl ammonium); aloe vera in any of its variety of forms (e.g., aloe vera gel); hyaluronic acid and derivatives thereof (e.g., salt derivatives such as sodium hyaluronate); lactamide monoethanolamine; acetamide monoethanolamine; urea; and, panthenol.
  • glycolic acid and glycolate salts e.g. ammonium and quaternary alkyl ammonium
  • lactic acid and lactate salts e.g. ammonium and quaternary alkyl ammonium
  • aloe vera in any of its variety of forms (e.g., aloe vera gel); hyal
  • the humectants may be used singly or two or more humectants may be included in topical compositions of the invention.
  • aloe vera in one or more of its forms is preferred as being a naturally derived product.
  • one or more humectants may be included in effective amounts, advantageously from 0.01 - 2.5%wt, preferably from 0.01 - 2%wt. based on the total weight of the composition of which it forms a part.
  • the foaming topical compositions of the invention may include one or more constituents, particularly may include one or more essential oils which are selected to provide a so-called "aromatherapy benefit" to the user.
  • Essential oils are complex mixtures of different organic molecules, such as terpenes, alcohols, esters, aldehydes, ketones and phenols. Such essential oils are frequently extracted from naturally occurring botanical sources such as flowers, stems, leaves, roots and barks of aromatic plants. While essential oils may be used singly, it is also common to utilize blends of essential oils in order to provide a conjunctive aroma benefit, and possibly a therapeutic benefit as well.
  • essential oils providing an aromatherapy benefit may be incorporated into the topical compositions of the invention either as a single essential oil or as a mixture of two or more essential oils. It is also to be recognized when used, an essential oil providing an aromatherapy benefit may replace all or part of any further fragrance constituent including the fragrance constituents discussed above as many of the essential oils providing an aromatherapy benefit are pungent and odiferous. Such essential oils providing an aromatherapy benefit may be used singly, as blends or mixtures of essential oils, or in combination with other fragrancing constituents which may be synthetically produced or naturally derived, but need not be derived from or contain essential oils per se.
  • exemplary useful essential oils providing an aromatherapy benefit which may find use in the topical compositions of the invention include: Abies Sibirica oil, Amyi ⁇ s Balsamifera oil, Anise oil, Balm Mint oil, Basil oil, Bay oil, Bee Balm oil, Bergamot oil, Birch oil, Bitter Orange oil, Cabbage Rose oil, Calendula Officinalis oil, California Nutmeg oil, Camellia Sinensis oil, Capsicum Frutescers oleoresin, Caraway Oil, Cardamon Oil, Cedarwood Oil, Chamaecyparis Obtusa Oil, Chamomile Oil, Cinnamon Oil, Citronella Oil, Clary Oil, Clove Oil, Cloveleaf Oil, Coriander Oil, Coriander Seed Oil, Cyperus Esculentus Oil, Cypress
  • Preferred essential oils providing an aromatherapy benefit for use in the topical compositions of the present invention ' include one or more selected from chamomile oil, lavendin oil, lavender oil, grapefruit oil, lemon oil, line oil, mandarin orange oil, orange flower oil and orange oil.
  • Chamomile oil may be used to promote both a fresh, clean and attractive scent and possibly provide a stress-relaxing benefit to the user of the topical composition.
  • Lavender oil, and lavendin may be used to promote both a fresh and attractive scent and possibly also provide a stress-relaxing benefit to the user of the topical composition.
  • grapefruit oil, lemon oil, line oil, mandarin orange oil, orange flower oil and orange oil provide a clean citrus scent and may possibly impart a perceived therapeutic benefit as well when used.
  • these one or more essential oils providing an aromatherapy benefit are present in an amount about 0.00001 wt. % to about 1 wt. %, based on the total weight of the composition.
  • the one or more essential oils providing an aromatherapy benefit are present in an amount about 0.00005 wt. % to about 0.75 wt. %, and more preferably about 0.0001 wt. % to about 0.5 wt. % of the total weight of the composition.
  • these one or more essential oils providing an aromatherapy benefit may be used with our without the optional fragrancing constituent recited previously and may be used wholly or partially in place of said fragrancing constituent.
  • the topical compositions may include one or more antioxidant constituents.
  • antioxidants include but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetyl- cysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, glutathione, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbyl polypeptide).
  • Oil-soluble antioxidants suitable for use in the compositions of this invention include, but are not limited to, butylated hydroxytoluene, retinoids, tocopherols e.g., tocopherol acetate, tocotrienols, and ubiquinone.
  • Natural extracts containing antioxidants suitable for use in the topical compositions of this invention include but not limited to, extracts containing flavonoids and isoflavonoids and their derivatives, extracts containing resveratrol and the like.
  • examples of such natural extracts include grape seed, green tea, pine bark, propolis, and the like.
  • the total amount of such antioxidants are usually not in excess of 5%wt, preferably are present in amounts of from 0.0001 — 4%wt. based on the total weight of the topical composition of which it forms a part.
  • an one or more antioxidants constituents are necessarily present.
  • the topical compositions may include one or more vitamins.
  • vitamins which can be added include vitamin A, such as vitamin A oil, retinol, retinyl • acetate and retinyl palmitate; vitamin B, including vitamin B 2 such as riboflavin, riboflavin butyrate and flavin adenine nucleotide, vitamin B 6 such as pyridoxine hydrochloride, pyridoxine dioctanoate and pyridoxine tripalmitate, vitamin B 12 and its derivatives, and vitamin B 1S and its derivatives; vitamin C, such as L-ascorbic acid, L- ascorbic acid dipalmitic ester, sodium (L-ascorbic acid)-2 -sulfate and dipotassium L- ascorbic acid diphosphate; vitamin D, such as ergocalciferol and cholecarciferol; vitamin E, such as alpha-tocopherol, beta-tocopherol, gamma-tocopherol
  • one or more vitamins may be included in effective amounts, advantageously from 0.0001 - l%wt, preferably from 0.001 — 0.75%wt. based on the total weight of the composition of which it forms a part.
  • the topical compositions may include one or more light stabilizers as well as UV absorbers. Such materials are known to be useful in cosmetic or topical compositions and impart a degree of stability to the compositions which may comprise one or more components which may be deleteriously affected when exposed to certain sources of light, e.g., sunlight, fluorescent light sources. Other such materials are known to stabilize or improve the effect of colorants which may be present in the compositions. Any cosmetically acceptable material or compound which provides protection for one or more of the constituents in the inventive compositions from photolytic degradation or photo- oxidative degradation may be used.
  • Exemplary light stabilizers as well as UV absorbers include: triazines including s- triazine, triazine derivatives e.g. 2,4,6-trianilino-(p-carbo-2'-ethyl-r-hexyloxy)-l,3,5- triazine, anisotriazine, ethylhexyltriazone, diethylhexylbutamidotriazone, 2,4,6- tris(diisobutyl 4'-aminobenzalmalonate)-s-triazine and octyltriazone; benzotriazoles and derivatives, e.g.
  • drometrizole trisiloxane ethylenebis(benzotriazolyl)tetramethylbutylphenol
  • benzophenone compounds and derivatives e.g., 2-hydroxy-4-methoxy benzophenone, 2-hydroxy-4-methoxy-4'-methyl benzophenone, n-hexyl 2-(4-diethylamino-2-hydroxybenzoyl)benzoate and 2,2'- dihydroxy-4-methoxy benzophenone as well as those materials currently marketed under the UVINUL tradename by BASF
  • sulphonic acid derivatives of benzophenones e.g., 2- hydroxy-4-methoxybenzophenon-5-sulphonic acid
  • esters of benzalmalonic acid e.g., 4- methoxy benzmalonic acid 2-ethylhexyl esters of benzalmalonic acid
  • benzoxazole derivatives e.g., 2,4- ⁇ w[5-l(dimethylpropyl)benzo
  • phenylbenzimidazoles and sulfonated benzimidazoles e.g., 2-phenylbenzimidazol-5- sulphonic acid, disodium phenyl dibenzimidazole tetrasulfonate
  • salicylic acid derivatives including esters of salicylic acid, e.g., ethylhexyl salicylate, dipropylene glycol salicylate, TEA salicylate, salicylic acid 2-ethylhexylester, salicylic acid 4-isopropyl benzylester, salicylic acid homomenthylester; compounds or derivatives of compounds based on benzylidenecamphor, e.g., 3-benzyliden camphor, 3-benzylidene norcamphor, 4- methylbenz
  • Exemplary and preferred such materials which are presently commercially available include one or more of: CIBAFAST H liquid, described to be sodium benzotriazolyl butylphenol sulfonate with Buteth-3 and tributyl citrate; TINOGARD HS described to be sodium benzotriazolyl butylphenol sulfonates; TESfOGARD AS described to be bumetrizole; TINOGARD TL described to be benzotriazolyl dodecyl p-cresol; and TINOGARD Q described to be tris(tetramethylhydroxypiperidinol) citrate, all of which are presently commercially available from Ciba Specialty Chemicals (Muttenz, CH.). Particularly preferred such materials are those sold under the UVTNUL trademark, (ex. BASF), particularly UVINUL MS 40.
  • the one or more light stabilizers as well as UV absorbers may be included in any effective amount; advantageously such materials are present in amounts of from 0.0001 - l%wt, preferably from 0.001 - 0.25%wt. based on the total weight of the composition of which it forms a part.
  • pH adjusting agents include phosphorus containing compounds, monovalent and polyvalent salts such as of silicates, carbonates, and borates, certain acids and bases, tartrates and certain acetates.
  • pH adjusting agents include mineral acids, basic compositions, and organic acids, which are typically required in only minor amounts.
  • pH buffering compositions include the alkali metal phosphates, polyphosphates, pyrophosphates, triphosphates, tetraphosphates, silicates, metasilicates, polysilicates, carbonates, hydroxides, and mixtures of the same.
  • Certain salts such as the alkaline earth phosphates, carbonates, hydroxides, can also function as buffers. It may also be suitable to use as buffers such materials as aluminosilicates (zeolites), borates, aluminates and certain organic materials such as gluconates, succinates, maleates, and their alkali metal salts.
  • the pH adjusting agent especially the pH buffers are present in an amount effective in order to maintain the pH of the inventive composition within a desired or a target pH range.
  • they may be included in generally minor amounts such as from 0.001 - 1.5 %wt. but desirably are present in amounts from 0.01 - l%wt. .
  • Exemplary and preferred pH buffers and pH adjusting agents are described with reference to one or more of the following Examples.
  • the inventive compositions may include one or more chelating agents.
  • chelating agents include those known to the art, including by way of non-limiting example; aminopolycarboxylic acids and salts thereof wherein the amino nitrogen has attached thereto two or more substituent groups.
  • Preferred chelating agents include acids and salts, especially the sodium and potassium salts of ethylenediaminetetraacetic acid, diethylenetriaminepentaacetic acid, N- hydroxyethylethylenediaminetriacetic acid, and of which the sodium salts of ethylenediaminetetraacetic acid may be particularly advantageously used.
  • Such chelating agents may be omitted, or they may be included in generally minor amounts such as from 0.001 - 0.5 %wt.
  • such chelating agents are included in the present inventive composition in amounts from 0.01 - 0.5%wt., but are most desirably present in reduced weight percentages from about 0.01 - 0.2%wt.
  • compositions according to the invention are largely aqueous in nature.
  • Water is added to order to provide to 100% by weight of the compositions of the invention.
  • the water may be tap water, but is preferably distilled and is most preferably deionized water or "soft" water. If the water is tap water, it is preferably substantially free of any undesirable impurities such as organics or inorganics, especially minerals salts which are present in hard water which may thus undesirably interfere with the operation of the constituents present in the topical compositions according to the present invention.
  • the present invention also contemplates a method for providing a cleaning and/or providing an antimicrobial benefit to skin or other topical surface which method contemplates the topical application of the aqueous foaming topical composition as described herein in a cleaning and/or antimicrobially effective amount.
  • a durable antimicrobial benefit is provided to the skin or other topical surface to which the composition has been applied.
  • topical compositions disclosed herein find a primary use in application to the skin to provide a cleaning and/or antimicrobial benefit thereto and is contemplated as being provided in a dispenser for use in such a treatment, it is to be understood that this is not to be understood as a limiting definition and that other forms and other uses of the present inventive composition, such as face lotion, milky lotion, cream, face cleansing cream, massage materials, liquid toilet soap, as well as in hair care products such as shampoo, rinse or other hair or scalp treatment are expressly contemplated as being within the scope of the present invention.
  • the topical composition of the invention can be formulated as a lotion, a cream or a gel, which may be transparent, translucent or opaque.
  • the topical composition is provided as a translucent or transparent, preferably a transparent composition.
  • the composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer.
  • a lotion or cream can be packaged in a bottle, or can be packaged with a propellant in a propellant-driven aerosol device or a may be packaged in a container fitted with a manually operable pump.
  • the inventive composition can be provided and stored in a non-deformable bottle but more preferably is provided in a squeezable container, such as a tube or deformable bottle which provides for easy dispensing of the composition by the consumer.
  • a further aspect of the invention provides a closed container containing the inventive composition as described herein.
  • topical application of the topical composition disclosed herein maybe applied to the skin on any part of the body, including the skin on the face, neck, chest, back, arms, axilla, hands, legs, and scalp.
  • the the topical composition disclosed herein may also be used on the hair.
  • the consumer dispenses a quantity of the topical composition described herein and applied it to the skin or any other part of the body which has preferably been wetted with water (e.g, rinsed) prior to application of the topical composition.
  • the topical composition may be rubbed into the applied skin or other part of the body by the consumer to generate a lather or foam, and thereafter it is expected that the treated area is rinsed by the consumer under a stream of running water, e.g, in a shower or by immersion into water, e.g, a bath. Thereafter the skin or other parts of the body of the consumer is permitted to air dry or the use of one or more towels to absorb excess moisture is also contemplated.
  • a further aspect of the invention is directed to the use of the foaming topical composition as described herein.
  • compositions according to the present invention were produced according to the invention described below were produced in according to the following general protocol:
  • a measured amount of deionized or soft water at 65° - 70°C was provided Into a first suitably sized vessel open to the atmosphere provided with a conventional laboratory stirrer, a measured amount of deionized or soft water at 65° - 70°C was provided. Thereafter under stirring was added the thickener constituent(s) to the water which was allowed to mix until uniform, after which was subsequently added the anionic surfactant(s) which was allowed to mix for at least 30 minutes following the addition of the anionic surfactant(s).
  • a further aliquot of the deionized water or soft water at 65° - 70°C was added, under stirring, the antimicrobial constituent and when present, the co-surfactant constituent was added and stirring continued until a uniform mixture was achieved.
  • the contents of the second vessel were added under stirring to the first vessel after the anionic surfactant(s) has been mixed at least 30 minutes in the first vessel.
  • a third suitably sized vessel similarly open to the atmosphere and provided with a further laboratory stirrer was provided was provided a further aliquot of the deionized water or soft water at 65° - 70°C to which was added, under stirring, the glycol and salicylic acid and stirring was allowed to mix until a homogeneous mixture was made. Subsequently the contents of this third vessel was added under stirring to the first vessel which contained the homogenous mixture of the first and second vessels' contents.
  • a fourth suitably sized vessel similarly open to the atmosphere and provided with a further laboratory stirrer was provided was provided a further aliquot of the deionized water or soft water at 65° - 70°C to which was added, under stirring, any buffers, e.g., citric acid, citric acid dehydrate, etc. and chelating agents until a homogenous mixture was produced. Subsequently the contents of this fourth vessel was added under stirring to the first vessel which contained the homogenous mixture of the first, second and third vessels' contents, after which the contents of the first vessel were allowed to cool to 40°C under stirring, after which was added any fragrance, preservative or colorant (dyestuff, pigment) constituents and allowed to homogenize. If needed to achieve a target viscosity, sodium chloride was added to the stirring composition.
  • any buffers e.g., citric acid, citric acid dehydrate, etc.
  • chelating agents e.g., citric acid, citric acid dehydrate, etc.
  • the speed of the stirrer was slowed to a minimal amount, and under such conditions the cosmetic particulate component was added to the composition in the first vessel and allowed to be uniformly dispersed in the bulk phase of the topical composition.
  • the pH of the as-mixed topical composition was evaluated, and if needed an small amount of an acid or a base was added under stirring to adjust the composition to a pH in the range of 4 - 4.5.
  • the constituents were used "as supplied” from their respective suppliers and may constitute less than 100%wt. "actives”, or may have been supplied as constituting 100%wt. "active" of the named compound, as indicated in the following Tables 1 and 2.
  • compositions according to Table 1 were evaluated at various temperatures and for various time intervals to evaluate their storage stability.
  • compositions were subjected to freeze/thaw stability evaluation wherein the characteristics of the composition were observed at room temperature (68°F, 20 0 C), after being frozen and permitted to return to room temperature, as well at a reduced temperature of 4°C.
  • the topical antimicrobial efficacy of a composition according to the invention was evaluated in accordance with EN12054 - Chemical Disinfectants and antiseptics - Quantitative suspension test for the evaluation of antimicrobial activity. This test is used to evaluate the antimicrobial efficacy of test compositions for hygienic and surgical handrab and handwash applications.
  • composition according to El as disclosed on Table 1 above iut adjusted to a pH of 4.35 was evaluated in accordance with EN12054. For each challenge organism, two replicates were used in each test. The following Table 4 reports the logm reduction achieved as well as the % log reduction for the identified challenge organisms.
  • the El composition according to the invention exhibited excellent antimicrobial activity.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cosmetics (AREA)

Abstract

L'invention porte sur des compositions topiques moussantes aqueuses qui fournissent un effet antimicrobien topique et qui contiennent une dispersion de matières particulaires cosmétiques en suspension de façon stable. L'effet antimicrobien est fourni par l'acide salicylique conjointement avec au moins un autre composé actif antimicrobien. Le système épaississant comprend un polymère réticulé de polyacrylate et un ou plusieurs polysaccharides polymères.
PCT/GB2008/000255 2007-03-14 2008-01-25 Compositions topiques ayant des particules en suspension WO2008110740A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0704884.6 2007-03-14
GB0704884A GB2447478A (en) 2007-03-14 2007-03-14 Aqueous topical compositions with antimicrobial benefit
GB0712987.7 2007-07-05
GB0712987A GB2447520A (en) 2007-03-14 2007-07-05 Aqueous topical compositions with antimicrobial benefit

Publications (1)

Publication Number Publication Date
WO2008110740A1 true WO2008110740A1 (fr) 2008-09-18

Family

ID=37988944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/000255 WO2008110740A1 (fr) 2007-03-14 2008-01-25 Compositions topiques ayant des particules en suspension

Country Status (5)

Country Link
CN (1) CN101631527A (fr)
AR (1) AR065780A1 (fr)
GB (2) GB2447478A (fr)
WO (1) WO2008110740A1 (fr)
ZA (1) ZA200906178B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931665A1 (fr) * 2008-05-30 2009-12-04 Oreal Procede de traitement des cheveux.
WO2012041831A3 (fr) * 2010-09-29 2013-05-30 Henkel Ag & Co. Kgaa Produit cosmétique nettoyant
WO2014168762A1 (fr) * 2013-04-09 2014-10-16 International Business Machines Corporation Polycarbonates cationiques antimicrobiens
US9999633B2 (en) 2013-04-09 2018-06-19 International Business Machines Corporation Antimicrobial cationic polycarbonates

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010013272A1 (de) * 2010-03-29 2011-09-29 Beiersdorf Ag Mikrobiologisch stabile anwendungsfreundliche Zubereitung mit Verdickern
DE102017114423A1 (de) * 2017-06-28 2019-01-03 Schülke & Mayr GmbH Verwendung von Alkylresorcinolen zur Verbesserung der Wirksamkeit von Kosmetikkonservierungsstoffen

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040816A1 (fr) * 1996-05-02 1997-11-06 The Procter & Gamble Company Compositions topiques comportant un complexe de tensio-actifs disperses
WO1998055093A1 (fr) * 1997-06-04 1998-12-10 The Procter & Gamble Company Composition nettoyante liquide antimicrobienne douce a rincer
US6294186B1 (en) * 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
WO2003030807A1 (fr) * 2001-10-04 2003-04-17 Beiersdorf Ag Produit cosmetique de nettoyage
GB2417959A (en) * 2004-09-11 2006-03-15 Reckitt Benckiser Inc Cleaning and sanitizing compositions
WO2007031756A1 (fr) * 2005-09-16 2007-03-22 Reckitt Benckiser Inc Compositions topiques moussantes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602611D0 (en) * 1996-02-09 1996-04-10 Unilever Plc Cosmetic composition
WO1999039683A1 (fr) * 1998-02-06 1999-08-12 The Procter & Gamble Company Composition de shampooing antipelliculaire, comprenant un agent donnant une sensation de fraicheur
DE10113054A1 (de) * 2001-03-15 2002-09-26 Beiersdorf Ag Selbstschäumende oder schaumförmige Zubereitungen mit anorganischen Gelbildnern, organischen Hydrokolloiden und partikulären hydrophoben und/oder hydrophobisierten und/oder ölabsorbierenden Festkörpersubstanzen
US7018422B2 (en) * 2001-10-18 2006-03-28 Robb Richard Gardner Shrink resistant and wrinkle free textiles
US20030228270A1 (en) * 2002-06-10 2003-12-11 Erika Tazberik Foaming clay cleanser composition
JP2007508243A (ja) * 2003-08-04 2007-04-05 フォーミックス エルティーディー． 両親媒性コポリマーゲル化剤を含む泡坦体
US20060177505A1 (en) * 2005-01-31 2006-08-10 L'oreal Cleaning composition in solid form

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040816A1 (fr) * 1996-05-02 1997-11-06 The Procter & Gamble Company Compositions topiques comportant un complexe de tensio-actifs disperses
WO1998055093A1 (fr) * 1997-06-04 1998-12-10 The Procter & Gamble Company Composition nettoyante liquide antimicrobienne douce a rincer
US6294186B1 (en) * 1997-06-04 2001-09-25 Peter William Beerse Antimicrobial compositions comprising a benzoic acid analog and a metal salt
WO2003030807A1 (fr) * 2001-10-04 2003-04-17 Beiersdorf Ag Produit cosmetique de nettoyage
GB2417959A (en) * 2004-09-11 2006-03-15 Reckitt Benckiser Inc Cleaning and sanitizing compositions
WO2007031756A1 (fr) * 2005-09-16 2007-03-22 Reckitt Benckiser Inc Compositions topiques moussantes

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2931665A1 (fr) * 2008-05-30 2009-12-04 Oreal Procede de traitement des cheveux.
WO2012041831A3 (fr) * 2010-09-29 2013-05-30 Henkel Ag & Co. Kgaa Produit cosmétique nettoyant
WO2014168762A1 (fr) * 2013-04-09 2014-10-16 International Business Machines Corporation Polycarbonates cationiques antimicrobiens
GB2526953A (en) * 2013-04-09 2015-12-09 Ibm Antimicrobial cationic polycarbonates
US9357772B2 (en) 2013-04-09 2016-06-07 International Business Machines Corporation Antimicrobial cationic polycarbonates
US9631050B2 (en) 2013-04-09 2017-04-25 International Business Machines Corporation Antimicrobial cationic polycarbonates
US9999633B2 (en) 2013-04-09 2018-06-19 International Business Machines Corporation Antimicrobial cationic polycarbonates
US10786530B2 (en) 2013-04-09 2020-09-29 International Business Machines Corporation Antimicrobial cationic polycarbonates

Also Published As

Publication number Publication date
GB2447520A (en) 2008-09-17
CN101631527A (zh) 2010-01-20
ZA200906178B (en) 2010-10-27
AR065780A1 (es) 2009-07-01
GB0712987D0 (en) 2007-08-15
GB0704884D0 (en) 2007-04-18
GB2447478A (en) 2008-09-17

Similar Documents

Publication Publication Date Title
US20080247960A1 (en) Foaming Tropical Compositions
US20130280312A1 (en) Skin Sanitizer Compositions Comprising Alcohol Based Emulsion
CA2579583C (fr) Compositions de citrate de dihydrogene d'argent
AU2020220554B2 (en) Topical sanitizing compositions
JP5206924B2 (ja) 洗浄剤組成物
WO2004004677A1 (fr) Compositions ayant une meilleure capacite a deposer sur une surface un compose actif topiquement
US20120184626A1 (en) Germicidal topical compositions
CN101262842B (zh) 起泡局部组合物
WO2008110740A1 (fr) Compositions topiques ayant des particules en suspension
KR20140129195A (ko) 중합체를 사용한 살생물제의 항미생물 활성의 증진
JP6065187B2 (ja) 起泡性局所抗菌洗浄組成物
KR20110087307A (ko) 알코올 제균 시트용 약액 및 그것을 포함하는 알코올 제균 시트
WO2010063988A1 (fr) Compositions germicides topiques
JP2013528638A (ja) 局所用殺菌組成物
EP1883390B1 (fr) Compositions topiques
EP2787819A2 (fr) Composition microbicide
WO2022112764A1 (fr) Compositions de soins personnels

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880008039.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701928

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 6045/CHENP/2009

Country of ref document: IN

122 Ep: pct application non-entry in european phase

Ref document number: 08701928

Country of ref document: EP

Kind code of ref document: A1

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0808810

Country of ref document: BR

Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE A PROCURACAO APRESENTADA NAO POSSUI DATA.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0808810

Country of ref document: BR

Free format text: PEDIDO RETIRADO EM RELACAO AO BRASIL POR NAO ATENDER AS DETERMINACOES REFERENTES A ENTRADA DO PEDIDO NA FASE NACIONAL E POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI NO2277 DE 26/08/2014

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载